Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-1 PREVENT
2022-502779-40-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Inclisiran with Placebo (2 arms). Primary endpoint: Time to first occurrence of 4-point major adverse cardiovascular events. Planned start Sep 2023; status: authorised.
02
Drugs
inclisiran
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2022-502779-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502779-40-00.